Cite
HARVARD Citation
Apolo, A. et al. (2022). Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. European journal of cancer. pp. 63-71. [Online].